PMID- 17045090
OWN - NLM
STAT- MEDLINE
DCOM- 20061114
LR  - 20211203
IS  - 0093-7754 (Print)
IS  - 0093-7754 (Linking)
VI  - 33
IP  - 5
DP  - 2006 Oct
TI  - Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status 
      and future applications.
PG  - 607-13
AB  - Significant achievements in the basic sciences have led to a greater knowledge of 
      the underlying signaling pathways in renal cell cancer (RCC), including the 
      mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt 
      pathway). The mTOR pathway has a central role in the regulation of cell growth 
      and increasing evidence suggests its dysregulation in cancer. Receiving input 
      from multiple signals, including growth factors, hormones, nutrients, and other 
      stimulants or mitogens, the pathway stimulates protein synthesis by 
      phosphorylating key translation regulators such as ribosomal S6 kinase. The mTOR 
      pathway also contributes to many other critical cellular functions, including 
      protein degradation and angiogenesis. Hence, use of inhibitors of the pathway 
      represents a new strategy for the targeted treatment of RCC, and mTOR inhibitors 
      have already shown promising clinical efficacy and low toxicity profiles in 
      unselected patients with metastatic RCC. As with other new, targeted cancer 
      agents, the future use of mTOR inhibitors will benefit from reproducible 
      biomarkers that can be used in the clinic to identify patients most likely to 
      respond and to document modulation of the drug target in addition to clinical 
      response.
FAU - Pantuck, Allan J
AU  - Pantuck AJ
AD  - Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 
      90095-1738, USA. apantuck@mednet.ucla.edu
FAU - Thomas, George
AU  - Thomas G
FAU - Belldegrun, Arie S
AU  - Belldegrun AS
FAU - Figlin, Robert A
AU  - Figlin RA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Enzyme Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Carcinoma, Renal Cell/*drug therapy/metabolism
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/metabolism
MH  - Protein Kinases/*drug effects
MH  - TOR Serine-Threonine Kinases
RF  - 52
EDAT- 2006/10/19 09:00
MHDA- 2006/11/15 09:00
CRDT- 2006/10/19 09:00
PHST- 2006/10/19 09:00 [pubmed]
PHST- 2006/11/15 09:00 [medline]
PHST- 2006/10/19 09:00 [entrez]
AID - S0093-7754(06)00268-5 [pii]
AID - 10.1053/j.seminoncol.2006.06.002 [doi]
PST - ppublish
SO  - Semin Oncol. 2006 Oct;33(5):607-13. doi: 10.1053/j.seminoncol.2006.06.002.